NCT04007029View on ClinicalTrials.gov

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
CD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Tocilizumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Parker Institute for Cancer Immunotherapy

OTHER

lead

Jonsson Comprehensive Cancer Center

OTHER